Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 12—December 2021
Research

Novel Assay to Measure Seroprevalence of Zika Virus in the Philippines

Cameron Adams, Ramesh Jadi, Bruno Segovia-Chumbez, Jedas Daag, Michelle Ylade, Freddy A. Medina, Tyler M. Sharp, Jorge L. Munoz-Jordan, In-Kyu Yoon, Jacqueline Deen, Anna Lena Lopez1, Aravinda M. de Silva, and Lakshmanane PremkumarComments to Author 
Author affiliations: University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA (C. Adams, R. Jadi, B. Segovia-Chumbez, A.M. de Silva, L. Premkumar); University of the Philippines, Manila, Philippines (J. Daag, M. Ylade, J. Deen, A.L. Lopez); Centers for Disease Control and Prevention, San Juan, Puerto Rico, USA (F.A. Medina, T.M. Sharp, J.L. Munoz-Jordan); Coalition for Epidemic Preparedness Innovations, Washington, DC, USA (I.-K. Yoon)

Main Article

Figure 3

Durability of ZIKV EDIII antibodies in study of novel assay to measure ZIKV seroprevalence in the Philippines. Longitudinal samples from patients with PCR-confirmed ZIKV infections were collected 1–600 days after symptom onset and tested for ZIKV EDIII–binding antibodies. DENV serostatus was determined by DENV focus reduction neutralization test. Primary ZIKV serostatus indicates ZIKV infection in DENV-naive participants; secondary ZIKV serostatus indicates ZIKV infection in participants previously infected with DENV. DENV, dengue virus; EDIII, E protein domain III; ZIKV, Zika virus.

Figure 3. Durability of ZIKV EDIII antibodies in study of novel assay to measure ZIKV seroprevalence in the Philippines. Longitudinal samples from patients with PCR-confirmed ZIKV infections were collected 1–600 days after symptom onset and tested for ZIKV EDIII–binding antibodies. DENV serostatus was determined by DENV focus reduction neutralization test. Primary ZIKV serostatus indicates ZIKV infection in DENV-naive participants; secondary ZIKV serostatus indicates ZIKV infection in participants previously infected with DENV. DENV, dengue virus; EDIII, E protein domain III; ZIKV, Zika virus.

Main Article

1Deceased.

Page created: August 25, 2021
Page updated: November 19, 2021
Page reviewed: November 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external